Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics


Iterum Therapeutics plc - Ordinary Share (ITRM): $2.03

0.02 (+1.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ITRM Stock Summary

  • Iterum Therapeutics plc's stock had its IPO on May 25, 2018, making it an older stock than only 4.47% of US equities in our set.
  • ITRM's price/sales ratio is 1,370.36; that's higher than the P/S ratio of 99.56% of US stocks.
  • Revenue growth over the past 12 months for Iterum Therapeutics plc comes in at -95.74%, a number that bests just 0.64% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ITRM, based on their financial statements, market capitalization, and price volatility, are SCYX, CBMG, TOCA, INO, and ITCI.
  • ITRM's SEC filings can be seen here. And to visit Iterum Therapeutics plc's official web site, go to www.iterumtx.com.

ITRM Stock Price Chart Interactive Chart >

Price chart for ITRM

ITRM Price/Volume Stats

Current price $2.03 52-week high $2.99
Prev. close $2.01 52-week low $0.45
Day low $1.95 Volume 6,454,900
Day high $2.05 Avg. volume 19,016,742
50-day MA $1.32 Dividend yield N/A
200-day MA $1.17 Market Cap 363.65M

Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.


ITRM Latest News Stream


Event/Time News Detail
Loading, please wait...

ITRM Latest Social Stream


Loading social stream, please wait...

View Full ITRM Social Stream

Latest ITRM News From Around the Web

Below are the latest news stories about Iterum Therapeutics plc that investors may wish to consider to help them evaluate ITRM as an investment opportunity.

Shareholders May Not Be So Generous With Iterum Therapeutics plc's (NASDAQ:ITRM) CEO Compensation And Here's Why

In the past three years, the share price of Iterum Therapeutics plc ( NASDAQ:ITRM ) has struggled to grow and now...

Yahoo | June 17, 2021

Crestone Joins Antimicrobials Working Group

The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 12 antimicrobial drug companies.

Yahoo | June 8, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We've got one more day of trading left in the week and we're starting it off with the biggest-pre-market stock movers for Friday!

William White on InvestorPlace | May 28, 2021

Iterum Therapeutics Stock Shoots Higher As Sulopenem Application Review On Track

Iterum Therapeutics plc (NASDAQ: ITRM ) has concluded a late-cycle meeting with the FDA related to its application for sulopenem etzadroxil/probenecid. Sulopenem is under review as a treatment for uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen. The agency … Full story available on Benzinga.com

Benzinga | May 28, 2021

Why Iterum Therapeutics Stock Soared Today

The big gain came after the company announced that the U.S. Food and Drug Administration (FDA) wouldn't require an advisory committee review of the regulatory filing for sulopenem etzadroxil/probenecid in treating urinary tract infections. Iterum submitted its filing in January of this year. The FDA originally planned to convene an advisory committee to review the application on June 2, 2021.

Yahoo | May 28, 2021

Read More 'ITRM' Stories Here

ITRM Price Returns

1-mo 79.65%
3-mo 21.56%
6-mo 107.78%
1-year 34.44%
3-year -83.50%
5-year N/A
YTD 105.26%
2020 -78.02%
2019 -10.18%
2018 N/A
2017 N/A
2016 N/A

Continue Researching ITRM

Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:

Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.7702 seconds.